



Sheet 1 of 1

Form PTO-1449  
(Rev. 8-83)  
(modified)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
13726US01SERIAL NO.  
10/000,107**INFORMATION DISCLOSURE CITATION**  
(Use several sheets if necessary)APPLICANT(s):  
SchoenhardFILING DATE  
October 30, 2001GROUP ART UNIT  
1645**RECEIVED**  
OCT 14 2003  
TECH CENTER 1600/2900**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	6,214,368	04/10/01	Lee	424	423	
	2001/006948	07/05/01	Kang et al.	514	44	

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NO.	PUBLICATIO N DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 02/098422 A1	12/2002	PCT				
	WO 03/037340 A1	05/2003	PCT				
	WO 01/85153 A2	11/2001	PCT				

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

	Then, "Potentiation by EDTA and levallorphan of the effect of sulfamethoxazole-trimethoprim on Escherichia coli, Experientia. Switzerland vol. 28(9):1118-1119 (September 15, 1972)
	Gekker, et al., "Naltrexone potentiates anti-HIV-1 activity of antiretroviral drugs in CD4+ lymphocyte cultures" Drug and Alcohol Dependence 64(3):257-263 (November, 2001)
	Lovekamp, et al., Inhibition of Human Multidrug Resistance P-glycoprotein 1 by Analogues of a Potent Delta-Opioid Antagonist, 902:131-134 (2001)
	PCT International Search Report, Application No. PCT/US02/17153 dated 7/7/03

EXAMINER

DATE CONSIDERED:

\*EXAMINER: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.